Core Insights - The flu season in China has reached a high epidemic level, with a significant increase in the purchase of flu-related medications across various regions, particularly in East and Central China, where orders for antiviral drugs have surged by over 80% and 95% respectively since December [1][2] Group 1: Medication Trends - The demand for antiviral medications, especially for influenza, has increased dramatically, with orders for the drug Marbofloxacin doubling in some areas [1] - Commonly used antiviral drugs include Oseltamivir (oral) and Peramivir (intravenous), along with RNA polymerase inhibitors like Marbofloxacin, which is suitable for patients aged 5 and above and requires only a single dose [2] Group 2: Preventive Measures - Specific high-risk children are advised to consider preventive medication during flu outbreaks, particularly those who have not achieved optimal immunity from vaccination or have been exposed to flu [3] - It is recommended that preventive medication be administered within 48 hours of exposure, continuing for up to 7 days, although it is not commonly recommended for infants under 3 months [3]

Group 1 - The flu season is currently at a high epidemic level in China, with a significant increase in the purchase of cold and flu medications across various regions, particularly in East China where orders for antiviral drugs have surged over 80% [1] - In central regions like Wuhan, the order volume for flu medications has increased by over 95%, with the specific antiviral drug, Marbofloxacin, seeing a 120% increase in orders [1] - The Chinese Center for Disease Control and Prevention has reported that the current flu epidemic is at a high level, prompting discussions on the appropriate use of medications to avoid excessive or inappropriate use [1] Group 2 - Common antiviral medications for flu include neuraminidase inhibitors such as Oseltamivir and Peramivir, as well as RNA polymerase inhibitors like Marbofloxacin, with different drugs having varying indications and treatment durations [2] - Oseltamivir is suitable for a wide range of patients, including those over 2 weeks old, with a standard treatment course of 5 days, extendable for severe or immunocompromised patients [2] - Marbofloxacin is indicated for patients aged 5 and above, requiring only a single dose for treatment [2] Group 3 - Specific groups of children may be considered for preventive antiviral treatment during flu outbreaks, including those with compromised immune systems or those who have not developed sufficient immunity after vaccination [3] - It is recommended that preventive medication be administered within 48 hours of exposure and continued for 7 days after the last exposure, although treatment is still advised even if started later [3] - Light symptom patients are advised to stay home and manage symptoms, while severe cases should receive early empirical antiviral treatment [3]

Group 1 - The flu season in Shanghai has started earlier this year, entering the peak period from late November to early January, with the dominant strain being H3N2 [1] - The so-called "K strain" circulating online is a variant of the H3N2 strain, not a new virus, as confirmed by health officials [1] - The current flu virus activity is at a high level, with multiple respiratory diseases posing risks due to fluctuating temperatures [1] Group 2 - Community health service centers in Shanghai are operating seven days a week to optimize testing and early identification of flu cases [2] - Medical institutions are enhancing their capacity for flu treatment, ensuring that fever clinics in secondary hospitals are fully operational and equipped [2] - The city is improving the medical process, including pre-examination and triage, and utilizing "Internet + healthcare" for online consultations [2] Group 3 - It is recommended to get the flu vaccine before the season starts, ideally in October, as it takes 2 to 4 weeks to develop antibodies [3] - The flu vaccine can provide 70%-80% protection against severe illness, even if administered during the peak season [3] - Antiviral medications are categorized into two types: neuraminidase inhibitors and RNA polymerase inhibitors, with the best effect when taken within 48 hours of infection [3]

Group 1 - The core viewpoint of the article is that Hongbo Pharmaceutical (301230.SZ) has confirmed that Palivizumab is one of its commercialized products, which is suitable for treating influenza caused by common seasonal flu, type A influenza, or type B influenza [1]

Core Viewpoint - Hongbo Pharmaceutical (301230.SZ) has indicated that Palivizumab is one of its commercialized products, suitable for treating influenza viruses causing common influenza, type A influenza, or type B influenza [1] Group 1 - Hongbo Pharmaceutical's product Palivizumab is aimed at addressing various types of influenza viruses [1]

Group 1 - The core viewpoint of the report indicates a rising trend in flu activity in China since November, suggesting a short-term focus on the flu market [1] - The report highlights a significant structural recovery trend in the pharmaceutical sector after a prolonged valuation adjustment, with continued optimism for pharmaceutical innovation and investment recovery [1] - The report notes that the positive trend in the secondary market is expected to drive a rebound in primary market financing, with ongoing favorable conditions for CXO and upstream sectors [1] Group 2 - The report states that the positive rate of flu virus among outpatient and emergency cases is approximately 45%, predominantly driven by the H3N2 strain [1] - It mentions that the ILI% reported by sentinel hospitals in southern provinces is 7.8%, higher than the previous week and above the levels of 2022 and 2024, but lower than 2023 [1] - The report provides data on the main pathogens detected in flu-like cases, with influenza virus accounting for 44.8% of the samples tested [1] Group 3 - The report discusses various antiviral drugs for flu treatment, with significant sales growth for Oseltamivir and Baloxavir during the week of November 15-21, with increases of 237% and 180% year-on-year, respectively [2] - It highlights the importance of flu vaccination as a preventive measure, with a total of 373 batches of flu vaccines approved for release since January 2025, including 230 batches of quadrivalent vaccines, a 3% increase year-on-year [2] - The report notes a decline in the approval of trivalent vaccines, with 143 batches approved, representing an 18% year-on-year decrease [2]

Core Viewpoint - The flu season has intensified, leading to increased consultations and concerns about the effectiveness of the antiviral drug Oseltamivir, particularly regarding its resistance rates [1]. Group 1: Efficacy of Oseltamivir - Current data suggests that while there may be a slight decrease in sensitivity of Oseltamivir against H1N1 and H3N2 strains, the resistance rate is not significantly high, with WHO reporting it at under 2% [1]. - In China, the latest monitoring indicates that 3.99% of A(H1N1)pdm09 strains show reduced sensitivity to neuraminidase inhibitors, but this should not cause excessive alarm [1]. - Oseltamivir remains a crucial first-line treatment for influenza despite some cases of reduced sensitivity due to improper use of the medication [1]. Group 2: Treatment Recommendations - If a patient does not show improvement after 48 hours of taking Oseltamivir, it may be necessary to consider potential resistance and conduct sensitivity testing [1]. - Alternatives to Oseltamivir include RNA polymerase inhibitors such as Baloxavir, Laninamivir (for H1N1), and Favipiravir (for cases where other antivirals are ineffective) [2]. - For severe cases or patients unable to take oral medication, inhaled drugs like Zanamivir or intravenous options like Peramivir can be utilized [2]. Group 3: Guidelines for Use - It is advised that patients with symptoms should use antiviral medications under the guidance of healthcare professionals to ensure proper usage [2]. - The standard treatment course for Oseltamivir is 5 days, with a recommended dosage of 75mg twice daily for adults and adolescents over 13 [2]. - Vaccination against influenza is emphasized as an effective preventive measure, ideally completed before October each year to reduce the risk of complications and resistance [2].

Core Insights - Beijing has entered the influenza epidemic period earlier than usual, with the peak possibly already reached, as respiratory diseases account for 35%-40% of total daily consultations at the Capital Institute of Pediatrics [1][3][4] Group 1: Current Situation - The flu activity in Beijing has been increasing since late October, entering the epidemic phase by mid-November, approximately four weeks earlier than last year [3] - The daily consultation volume for respiratory diseases at the Capital Institute of Pediatrics reached this year's peak in the last two weeks, although it is slightly lower than previous years' peaks [4] Group 2: Measures Taken - To manage the winter surge in patient visits, the institute has increased personnel and appointment availability in respiratory, internal medicine, and fever clinics [4] - New online services have been introduced, including "external hospital follow-up" and dual appointment options for online and offline consultations, allowing for more efficient patient management [5] Group 3: Expert Insights - The resistance rate to Oseltamivir (Tamiflu) is currently between 1% and 2%, indicating that it remains effective against influenza [7] - It is crucial for children showing symptoms of influenza to receive antiviral treatment within 48 hours of onset to reduce the risk of severe illness [8]

Core Insights - The flu activity in China is rapidly increasing, with the overall flu epidemic at a moderate level, and Beijing has entered the peak period of flu [1][3] Group 1: Flu Situation and Monitoring - The Beijing Municipal Health Commission reported that the flu has reached its peak, with the circulating strain being H3N2, which is still below historical peaks compared to previous seasons [3] - A "three-medical linkage" monitoring and scheduling mechanism has been established by the Beijing Municipal Health Commission, Medical Insurance Bureau, and Drug Administration to ensure a balanced supply and demand of flu medications [3] Group 2: Vaccination and Preventive Measures - The flu vaccine in Beijing will continue to be available for self-paid vaccination until the end of February 2026, with various methods for citizens to make appointments [3] - Preventive medication is recommended primarily for high-risk individuals who have not been vaccinated or are in close contact with confirmed cases, with a recommended usage window of within 48 hours post-exposure [5] Group 3: Pediatric Care and Hospital Response - The Beijing Children's Hospital has seen a significant increase in respiratory disease consultations since November, with a 20% rise in patient visits noted in the third week of November [7] - The hospital has increased its medical staff by approximately 15% and is providing online consultations to reduce the risk of cross-infection during peak times [7][8] Group 4: Future Actions - The Beijing Municipal Health Commission will continue to closely monitor the disease's spread and ensure medical service support for children's respiratory diseases [9]

Core Insights - The flu positivity rate in China has approached 45%, indicating an overall epidemic level, with some provinces reaching high epidemic levels [2] - The predominant circulating strain is the H3N2 subtype, accounting for over 95% of cases, leading to increased demand for antiviral medications [2] - The sales of antiviral drugs have surged, with a reported increase of over 150% in northern cities like Shenyang and Changchun, and a 63% rise in testing orders on e-commerce platforms [2] Antiviral Drugs Overview - There are six types of antiviral drugs for influenza A in China: Baloxavir, Peramivir, Oseltamivir, Zanamivir, Rimantadine, and Onradivir [3] - Baloxavir is the first small molecule RNA polymerase inhibitor approved for clinical trials in China [3] Market Dynamics - As of March 2024, 66 companies in China have received 106 approvals for antiviral drugs, with Oseltamivir accounting for approximately 70% of the approvals [9] - The market is largely dominated by foreign companies holding core patents, with only a few domestic companies like Zhongsheng Pharmaceutical having original research capabilities [6][8] Impact on Schools - Schools have become significant sites for flu transmission, with a notable increase in reported outbreaks in childcare institutions and schools, particularly among children aged 5-14 [12]